INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
Public company

MAZEMaze Therapeutics, Inc.

CIK 0001842295

EDGAR filingsOpen in network
Disclosed transactions60
Buys / sells0 / 33
Max Insider Score46
Connections9with evidence

MAZE · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
CV
Coloma Jason VDirector, Chief Executive Officer
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$166K
5,345 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Insider ofevidence
    Coloma Jason VDirector, Chief Executive Officer · Sep 4, 2026
  • ← Insider ofevidence
    Courtney PhillipsGC and Corp. Secretary · Sep 4, 2026
  • ← Insider ofevidence
    Kornowski SophieDirector · Aug 17, 2026
6
CV
Coloma Jason VDirector, Chief Executive Officer
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL
$10K
336 sh
Nov 2, 2026
Nov 4, 2026
traded Nov 2, 2026
+2d
SEC FORM 4

Evidence

16
CV
Coloma Jason VDirector, Chief Executive Officer
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$799K
26.6K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

13
CV
Coloma Jason VDirector, Chief Executive Officer
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$68K
2,257 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

0
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$8,930
857 sh
Oct 29, 2026Oct 30, 2026
traded Oct 29, 2026
+1dSEC FORM 4

Evidence

0
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
6,643 sh
Oct 29, 2026Oct 30, 2026
traded Oct 29, 2026
+1dSEC FORM 4

Evidence

3
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$69K
6,643 sh
Oct 29, 2026Oct 30, 2026
traded Oct 29, 2026
+1dSEC FORM 4

Evidence

0
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
857 sh
Oct 29, 2026Oct 30, 2026
traded Oct 29, 2026
+1dSEC FORM 4

Evidence

10
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$241K
7,500 sh
Oct 29, 2026Oct 30, 2026
traded Oct 29, 2026
+1dSEC FORM 4

Evidence

21
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$435K
16.1K sh
Oct 1, 2026Oct 2, 2026
traded Oct 1, 2026
+1dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$168K
16.1K sh
Oct 1, 2026Oct 2, 2026
traded Oct 1, 2026
+1dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
16.1K sh
Oct 1, 2026Oct 2, 2026
traded Oct 1, 2026
+1dSEC FORM 4

Evidence

3
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$78K
7,500 sh
Sep 29, 2026Oct 1, 2026
traded Sep 29, 2026
+2dSEC FORM 4

Evidence

10
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$203K
7,500 sh
Sep 29, 2026Oct 1, 2026
traded Sep 29, 2026
+2dSEC FORM 4

Evidence

0
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
7,500 sh
Sep 29, 2026Oct 1, 2026
traded Sep 29, 2026
+2dSEC FORM 4

Evidence

31
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$255K
9,705 sh
Sep 4, 2026Sep 8, 2026
traded Sep 4, 2026
+4dSEC FORM 4

Evidence

36
CP
Courtney PhillipsGC and Corp. Secretary
MAZEMaze Therapeutics, Inc.
Open-market sale
SELL$6,590
243 sh
Sep 2, 2026Sep 4, 2026
traded Sep 2, 2026
+2dSEC FORM 4

Evidence

46
CV
Coloma Jason VDirector, Chief Executive Officer
MAZEMaze Therapeutics, Inc.
Open-market sale
SELL$260K
9,852 sh
Sep 2, 2026Sep 4, 2026
traded Sep 2, 2026
+2dSEC FORM 4

Evidence

32
CP
Courtney PhillipsGC and Corp. Secretary
MAZEMaze Therapeutics, Inc.
Open-market sale
SELL$567
22 sh
Sep 3, 2026Sep 4, 2026
traded Sep 3, 2026
+1dSEC FORM 4

Evidence

32
CV
Coloma Jason VDirector, Chief Executive Officer
MAZEMaze Therapeutics, Inc.
Open-market sale
SELL$3,325
129 sh
Sep 3, 2026Sep 4, 2026
traded Sep 3, 2026
+1dSEC FORM 4

Evidence

43
CP
Courtney PhillipsGC and Corp. Secretary
MAZEMaze Therapeutics, Inc.
Open-market sale
SELL$52K
1,990 sh
Sep 3, 2026Sep 4, 2026
traded Sep 3, 2026
+1dSEC FORM 4

Evidence

36
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Open-market sale
SELL$74K
2,800 sh
Sep 2, 2026Sep 4, 2026
traded Sep 2, 2026
+2dSEC FORM 4

Evidence

40
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale
SELL$133K
5,130 sh
Sep 3, 2026Sep 4, 2026
traded Sep 3, 2026
+1dSEC FORM 4

Evidence

46
CV
Coloma Jason VDirector, Chief Executive Officer
MAZEMaze Therapeutics, Inc.
Open-market sale
SELL$293K
11.3K sh
Sep 3, 2026Sep 4, 2026
traded Sep 3, 2026
+1dSEC FORM 4

Evidence

40
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale
SELL$118K
4,481 sh
Sep 2, 2026Sep 4, 2026
traded Sep 2, 2026
+2dSEC FORM 4

Evidence

36
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Open-market sale
SELL$83K
3,207 sh
Sep 3, 2026Sep 4, 2026
traded Sep 3, 2026
+1dSEC FORM 4

Evidence

29
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Open-market sale
SELL$929
36 sh
Sep 3, 2026Sep 4, 2026
traded Sep 3, 2026
+1dSEC FORM 4

Evidence

36
CV
Coloma Jason VDirector, Chief Executive Officer
MAZEMaze Therapeutics, Inc.
Open-market sale
SELL$37K
1,375 sh
Sep 2, 2026Sep 4, 2026
traded Sep 2, 2026
+2dSEC FORM 4

Evidence

29
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Open-market sale
SELL$11K
391 sh
Sep 2, 2026Sep 4, 2026
traded Sep 2, 2026
+2dSEC FORM 4

Evidence

29
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale
SELL$1,521
59 sh
Sep 3, 2026Sep 4, 2026
traded Sep 3, 2026
+1dSEC FORM 4

Evidence

40
CP
Courtney PhillipsGC and Corp. Secretary
MAZEMaze Therapeutics, Inc.
Open-market sale
SELL$46K
1,738 sh
Sep 2, 2026Sep 4, 2026
traded Sep 2, 2026
+2dSEC FORM 4

Evidence

29
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale
SELL$17K
625 sh
Sep 2, 2026Sep 4, 2026
traded Sep 2, 2026
+2dSEC FORM 4

Evidence

2
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise
M—
12.5K sh
Sep 1, 2026Sep 3, 2026
traded Sep 1, 2026
+2dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
20.0K sh
Sep 1, 2026Sep 3, 2026
traded Sep 1, 2026
+2dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
16.1K sh
Sep 1, 2026Sep 3, 2026
traded Sep 1, 2026
+2dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
20.0K sh
Sep 1, 2026Sep 3, 2026
traded Sep 1, 2026
+2dSEC FORM 4

Evidence

10
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise
M—
12.5K sh
Sep 1, 2026Sep 3, 2026
traded Sep 1, 2026
+2dSEC FORM 4

Evidence

31
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$426K
16.1K sh
Sep 1, 2026Sep 3, 2026
traded Sep 1, 2026
+2dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$168K
16.1K sh
Sep 1, 2026Sep 3, 2026
traded Sep 1, 2026
+2dSEC FORM 4

Evidence

3
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$78K
7,500 sh
Aug 28, 2026Aug 31, 2026
traded Aug 28, 2026
+3dSEC FORM 4

Evidence

24
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$207K
7,500 sh
Aug 28, 2026Aug 31, 2026
traded Aug 28, 2026
+3dSEC FORM 4

Evidence

4
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
7,500 sh
Aug 28, 2026Aug 31, 2026
traded Aug 28, 2026
+3dSEC FORM 4

Evidence

9
KS
Kornowski SophieDirector
MAZEMaze Therapeutics, Inc.
Grant or award
A—
36.0K sh
Aug 13, 2026Aug 17, 2026
traded Aug 13, 2026
+4dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$168K
16.1K sh
Aug 13, 2026Aug 14, 2026
traded Aug 13, 2026
+1dSEC FORM 4

Evidence

16
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$446K
16.1K sh
Aug 13, 2026Aug 14, 2026
traded Aug 13, 2026
+1dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
16.1K sh
Aug 13, 2026Aug 14, 2026
traded Aug 13, 2026
+1dSEC FORM 4

Evidence

21
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$400K
13.4K sh
Jul 1, 2026Jul 2, 2026
traded Jul 1, 2026
+1dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$152K
14.6K sh
Jul 1, 2026Jul 2, 2026
traded Jul 1, 2026
+1dSEC FORM 4

Evidence

15
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$36K
1,200 sh
Jul 1, 2026Jul 2, 2026
traded Jul 1, 2026
+1dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
14.6K sh
Jul 1, 2026Jul 2, 2026
traded Jul 1, 2026
+1dSEC FORM 4

Evidence

14
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$210K
7,500 sh
Jun 29, 2026Jul 1, 2026
traded Jun 29, 2026
+2dSEC FORM 4

Evidence

3
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$78K
7,500 sh
Jun 29, 2026Jul 1, 2026
traded Jun 29, 2026
+2dSEC FORM 4

Evidence

0
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
7,500 sh
Jun 29, 2026Jul 1, 2026
traded Jun 29, 2026
+2dSEC FORM 4

Evidence

9
AC
Andrews Nancy CDirector
MAZEMaze Therapeutics, Inc.
Grant or award
A—
18.0K sh
Jun 8, 2026Jun 10, 2026
traded Jun 8, 2026
+2dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
14.9K sh
Jun 1, 2026Jun 3, 2026
traded Jun 1, 2026
+2dSEC FORM 4

Evidence

15
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$42K
1,600 sh
Jun 1, 2026Jun 3, 2026
traded Jun 1, 2026
+2dSEC FORM 4

Evidence

21
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$339K
13.3K sh
Jun 1, 2026Jun 3, 2026
traded Jun 1, 2026
+2dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$155K
14.9K sh
Jun 1, 2026Jun 3, 2026
traded Jun 1, 2026
+2dSEC FORM 4

Evidence

3
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$78K
7,500 sh
May 29, 2026Jun 2, 2026
traded May 29, 2026
+4dSEC FORM 4

Evidence

14
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$198K
7,500 sh
May 29, 2026Jun 2, 2026
traded May 29, 2026
+4dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Andrews Nancy CDirector · Jun 10, 2026
  • ← Insider ofevidence
    Kumar NeilDirector · Mar 31, 2026
  • ← Insider ofevidence
    Bernstein HaroldPresident, R&D & CMO · Dec 31, 2025
  • ← Insider ofevidence
    Dandekar AtulCSBO · Dec 31, 2025
  • ← Insider ofevidence
    Bachrodt AmySVP, Finance · Dec 31, 2025